1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

Alison M. Schram, Kōichi Goto, Dongwook Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, K. Umemoto, Joon Oh Park, Natasha B. Leighl, Teresa Macarulla, Stephen V. Liu, M.N. Al-Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, Shola Adeyemi, Shekeab Jauhari, Alexander Drilon